RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
Patients with castration-refractory prostate cancer (PC) are a complicated group of patients for treatment. At the time of diagnosis, 85% of patients have a localized tumor process, however, in 40% of patients, generalization of the tumor process is observed. The most common localization of prostate...
Saved in:
| Main Authors: | A. A. Kostin, A. G. Muradyan, A. O. Tolkachev, S. V. Popov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2017-12-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/223 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Colleen Mackenzie, et al.
Published: (2024-10-01) -
Intravenous radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer
by: O. I. Kit, et al.
Published: (2024-12-01) -
Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
by: John Buscombe, et al.
Published: (2021-04-01) -
Factors Influencing Outcome Post–Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges
by: Amit Bhoil, et al.
Published: (2022-12-01) -
Multicenter, international, retrospective study of prognostic factors for Ra223
by: Takuya Oishi, et al.
Published: (2025-03-01)